[go: up one dir, main page]

AU2002211663A1 - Nf-$g(k)b inhibitors - Google Patents

Nf-$g(k)b inhibitors

Info

Publication number
AU2002211663A1
AU2002211663A1 AU2002211663A AU1166302A AU2002211663A1 AU 2002211663 A1 AU2002211663 A1 AU 2002211663A1 AU 2002211663 A AU2002211663 A AU 2002211663A AU 1166302 A AU1166302 A AU 1166302A AU 2002211663 A1 AU2002211663 A1 AU 2002211663A1
Authority
AU
Australia
Prior art keywords
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002211663A
Inventor
James F. Callahan
Amy K. Roshak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of AU2002211663A1 publication Critical patent/AU2002211663A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
AU2002211663A 2000-10-12 2001-10-12 Nf-$g(k)b inhibitors Abandoned AU2002211663A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23975900P 2000-10-12 2000-10-12
US60239759 2000-10-12
PCT/US2001/031866 WO2002030353A2 (en) 2000-10-12 2001-10-12 NF-λB INHIBITORS

Publications (1)

Publication Number Publication Date
AU2002211663A1 true AU2002211663A1 (en) 2002-04-22

Family

ID=22903601

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002211663A Abandoned AU2002211663A1 (en) 2000-10-12 2001-10-12 Nf-$g(k)b inhibitors

Country Status (4)

Country Link
EP (1) EP1324759A4 (en)
JP (1) JP2004523476A (en)
AU (1) AU2002211663A1 (en)
WO (1) WO2002030353A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003154D0 (en) * 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
WO2002041843A2 (en) 2000-10-26 2002-05-30 Tularik Inc. Antiinflammation agents
SE0102616D0 (en) 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
SE0102617D0 (en) 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
US7166639B2 (en) 2001-10-04 2007-01-23 Smithkline Beecham Corporation NF-κB inhibitors
CA2464924A1 (en) * 2001-10-30 2003-05-08 Pharmacia Corporation Heteroaromatic carboxamide derivatives for the treatment of inflammation
WO2003048152A2 (en) 2001-12-05 2003-06-12 Tularik Inc. Inflammation modulators
JP2005531608A (en) 2002-06-06 2005-10-20 スミスクライン・ビーチャム・コーポレイション NF-κB inhibitor
ATE358673T1 (en) 2002-06-06 2007-04-15 Smithkline Beecham Corp NF-κB INHIBITORS
AU2003270701B2 (en) 2002-10-31 2009-11-12 Amgen Inc. Antiinflammation agents
JP2006510676A (en) * 2002-12-06 2006-03-30 スミスクライン・ビーチャム・コーポレイション NF-κB inhibitor
SE0300092D0 (en) 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
SE0300091D0 (en) 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
JP2007502308A (en) 2003-08-15 2007-02-08 アストラゼネカ アクチボラグ Substituted thiophenes and their use
WO2005060711A2 (en) * 2003-12-19 2005-07-07 Elixir Pharmaceuticals, Inc. Methods of treating a disorder
CN100584840C (en) * 2004-01-05 2010-01-27 阿斯利康(瑞典)有限公司 Substituted Heterocyclic Compounds and Their Applications
TW200616967A (en) 2004-06-24 2006-06-01 Smithkline Beecham Corp Novel indazole carboxamides and their use
PE20060748A1 (en) 2004-09-21 2006-10-01 Smithkline Beecham Corp INDOLCARBOXAMIDE DERIVATIVES AS KINASE INHIBITORS IKK2
BRPI0611674A2 (en) 2005-06-30 2009-04-28 Smithkline Beecham Corp chemical compounds
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
AR065804A1 (en) 2007-03-23 2009-07-01 Smithkline Beecham Corp COMPOSITE OF INDOL CARBOXAMIDE, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT AND USE OF THIS COMPOUND TO PREPARE A MEDICINAL PRODUCT
AU2008266883B2 (en) 2007-06-20 2014-01-30 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
JP2011518195A (en) 2008-04-21 2011-06-23 オトノミ―，インク． Ear formulations and related applications to treat ear diseases and disorders
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
JP2011527680A (en) * 2008-07-09 2011-11-04 メルク・シャープ・エンド・ドーム・コーポレイション JANUS kinase inhibitors
US8354539B2 (en) 2009-03-10 2013-01-15 Glaxo Group Limited Indole derivatives as IKK2 inhibitors
WO2012046793A1 (en) * 2010-10-07 2012-04-12 参天製薬株式会社 Novel jak3 inhibitor containing, as active ingredient, thiophene derivative having ureido group and aminocarbonyl group as substituents
EP2520292A1 (en) 2011-05-06 2012-11-07 Helmholtz-Zentrum für Infektionsforschung GmbH Use of spirangiens for the treatment or prevention of IL-8 or IL-6 mediated disorders
WO2018005830A1 (en) 2016-06-29 2018-01-04 Otonomy, Inc. Triglyceride otic formulations and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1468012A (en) * 1973-08-09 1977-03-23 Beecham Group Ltd 2-amino-3-carboxy-thiophene derivatives
JPH06143838A (en) * 1992-11-06 1994-05-24 Sankyo Kagaku Kk Dye for thermal transfer recording
JP3236683B2 (en) * 1992-11-06 2001-12-10 大日本印刷株式会社 Dye for thermal transfer and thermal transfer sheet
PT853083E (en) * 1997-01-06 2001-12-28 Pfizer COMPOSITION OF PYRIDILFURANE AND PYRIDYLTHOPHENE AND ITS PHARMACEUTICAL UTILIZATION
GB0003154D0 (en) * 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
US6414013B1 (en) * 2000-06-19 2002-07-02 Pharmacia & Upjohn S.P.A. Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention

Also Published As

Publication number Publication date
EP1324759A2 (en) 2003-07-09
JP2004523476A (en) 2004-08-05
WO2002030353A3 (en) 2002-06-27
WO2002030353A2 (en) 2002-04-18
EP1324759A4 (en) 2004-05-12

Similar Documents

Publication Publication Date Title
AU2002211663A1 (en) Nf-$g(k)b inhibitors
AU2001258771A1 (en) -secretase inhibitors
AU2001237041A1 (en) Kinase inhibitors
AU2002250394A1 (en) Rho-kinase inhibitors
AU2002245709A1 (en) Rho-kinase inhibitors
AU4882101A (en) Mmp-12 inhibitors
AU2002220241A1 (en) Parb inhibitors
AU2001258784A1 (en) Tyrosine phosphatase inhibitors
AU2001254546A1 (en) Aminopiperidines
AU2001247589A1 (en) Non-amidine containing protease inhibitors
AU2001294557A1 (en) Thrombin inhibitors
AU2001279754A1 (en) Indoloquinazolinones
AU2001220281A1 (en) Rollerboard for road-skiing
AU2001265871A1 (en) Substituted sulfonylaminopyrimidines
AU2001258255A1 (en) Substituted benzoylcyclohexenones
AU2001254731A1 (en) Substituted phenyluracils
AU2001278997A1 (en) Thrombin inhibitors
AU2001246864A1 (en) Hypotensors
AU2001226668A1 (en) Crankshaft-starter-generator
AU2001295713A1 (en) Blast-processing
AU2002246675A1 (en) Thrombin inhibitors
AU2001256521A1 (en) Golf-putters
AU2001263003A1 (en) Carboxyalkylether-acat inhibitor combinations
AU2001284453A1 (en) Apoptosis inhibitors
AU2001264400A1 (en) Clothes-peg